Clinical Trial Details
— Status: Withdrawn
Administrative data
| NCT number |
NCT03824444 |
| Other study ID # |
A2935-R |
| Secondary ID |
|
| Status |
Withdrawn |
| Phase |
Early Phase 1
|
| First received |
|
| Last updated |
|
| Start date |
January 1, 2024 |
| Est. completion date |
January 23, 2024 |
Study information
| Verified date |
January 2024 |
| Source |
VA Office of Research and Development |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
An FDA Early Feasibility Study (EFS) allows for early clinical evaluation of devices to
provide proof of principle and initial clinical safety data. The Primary Aim of this proposal
is to perform an FDA guided EFS of a percutaneous osseointegrated (OI) docking system for
patients with transhumeral (above elbow) amputations, establishing its initial safety.
Success of the Primary Aim (Safety) will be determined over a one year follow-up period by
observing the rate of patients successfully using their device without removal. The Secondary
Aim of this proposal is to quantify the functional effectiveness of the OI device, giving
specific attention to protocol differences required for male and female patients. Success for
the Secondary Aim (Functional Effectiveness) will be to determine functional improvement with
the device compared to the pre-operative performance. This will be the first longitudinal
analyses to evaluate the percutaneous OI devices on objective functionality measures of
transhumeral amputation individuals.
Description:
An FDA Early Feasibility Study (EFS) allows "for early clinical evaluation of devices to
provide proof of principle and initial clinical safety data." Over the past four years, the
team has performed the first EFS clinical trial of a percutaneous osseointegrated (OI)
docking system for patients with transfemoral amputations. As of December 1, 2017, 10
transfemoral VA patients received the device and are ambulating successfully for up to
36-months with positive safety and functional results. Currently, the EFS safety and
functionality data are being used to target a pivotal study of the transfemoral device to
obtain Premarket Approval (PMA) that will result in the broad clinical introduction of the
transfemoral OI device within the US. However, transhumeral patients are currently
underserved by prosthetic technologies. Nearly 60% of transhumeral patients limit their use
of suspension-based prostheses and upwards of 30% of upper-limb suspension-type prosthetic
devices are completely abandoned by both the VA and the military patient populations-with
abandonment of the prosthesis most common among women. The overarching goal of this proposal
is to maximize the functional recovery of US Veteran, military, and civilian patients with
transhumeral limb loss. The investigators believe that this can be done by bringing FDA
approved percutaneous OI devices to this patient population. Over the past 3 years, the
investigators developed a unique percutaneous OI device, known here as PODS, specifically for
transhumeral patients using an evidence based approach.
The Primary Aim of this proposal is to perform an FDA guided EFS of the PODS device for
transhumeral patients, establishing its initial clinical safety. Transhumeral patients will
be recruited to the Salt Lake City (SLC) VA for in-depth consultation and functional
evaluation. Recruited candidates will undergo a full clinical evaluation of the residual
limb. Functional assessments, focusing on activities of daily living (ADL), and evaluation of
joint and terminal device biomechanics will be collected with their socket-prosthetic device
(time = 0). These data will be used for final patient selection (N=10) for inclusion in the
FDA EFS clinical trial. The EFS patients will be brought back to the SLC VA, admitted to the
hospital, and have the Stage 1 surgery to receive the PODS endoprosthetic device, and then
discharged to home. Approximately 4 weeks later, patients will return to the SLC VA and have
the Stage 2 procedure performed to place the percutaneous post and attach their prosthetic
device. Post-operatively, wound healing will be monitored at the percutaneous site. Patients
will be discharged from the hospital to continue outpatient rehabilitation. Periodically
(time = 3, 6, and 12 months) following the Stage 2 procedure, patients will be brought back
to the SLC VA for assessment of their residual bone, soft tissues and device. The functional
assessments will be repeated with their PODS device at each follow-up visit. Success of the
Primary Aim (Safety) will be determined for the 1-year follow-up period with patients
successfully using their PODS devices with no device removal due to deep bone infections,
aseptic loosening, or atraumatic fracture.
The Secondary Aim of this proposal is to quantify the functional effectiveness of the PODS
device, giving specific attention to protocol differences required for male and female
patients. Success for the Secondary Aim (Functional Effectiveness) will be to quantify the
degree to which patients achieve functional improvement with the PODS device compared to the
pre-operative performance. These data will be the first longitudinal analyses to evaluate the
impact of percutaneous OI prostheses on objective functionality measures of these
transhumeral amputation individuals.
